| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tb161-RAD402 | Tb161-RAD402 | Phase 2 Clinical | Radiopharm Theranostics Ltd | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| GEA-408 | GEA-408 | Phase 2 Clinical | GenEros Biopharma Hangzhou Ltd | Prostatic Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Afala | Approved | Materia Medica Holding Research And Production Company | Russian Federation | Prostatic Neoplasms; Prostatitis | Materia Medica Holding Research And Production Company | 2014-01-01 | Prostatic Neoplasms; Prostatitis | Details |